Current Management of Age-Related Macular Degeneration.
Age-related macular degeneration
Choroidal neovascularization
Diagnosis
Disease management
Geographic atrophy
Intravitreal injections
Office visits
Optical coherence tomography
Photodynamic therapy
Visual acuity
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
13
4
2021
pubmed:
14
4
2021
medline:
16
4
2021
Statut:
ppublish
Résumé
Age-related macular degeneration (AMD) remains a leading cause of blindness worldwide. The assessment and management of patients with this condition has evolved in the last decades. In this chapter, current standards for diagnosis, follow-up, and treatment of patients with AMD are reviewed and summarized. Namely, we highlight how current assessment has moved from conventional ophthalmoscopy and fluorescein angiography testing to a multimodal approach, and its important advantages. Alternatives to visual acuity for functional assessment of patients with AMD are also presented. Regarding strategies for follow-up and treatment, we provide specific information for the different stages (i.e., early, intermediate, and late) and forms (for example, choroidal neovascularization and geographic atrophy) of AMD. Specifically, we discuss the relevance and options for self-monitoring and non-pharmacological interventions. Additionally, a summary of the important trials (both on exudative and non-exudative AMD) that have helped inform clinical practice is provided, including data on antiangiogenic agents currently available, and outcomes of the different regimens that have been studied. The influence of advances in imaging on treatment strategies is also discussed.In summary, this chapter is a resource for all clinicians engaged in providing state of the art care for patients with AMD, and can help improve diagnosis, management, and outcomes of individuals with this blinding condition.
Identifiants
pubmed: 33848007
doi: 10.1007/978-3-030-66014-7_12
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
295-314Références
Age-Related Eye Disease Study Research Group (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119:1417–1436
doi: 10.1001/archopht.119.10.1417
Ferris FL, Davis MD, Clemons TE et al (2005) A simplified severity scale for age-related macular degeneration: AREDS report no. 18. Arch Ophthalmol 123:1570–1574. https://doi.org/10.1001/archopht.123.11.1570
doi: 10.1001/archopht.123.11.1570
pubmed: 16286620
Cukras C, Fine SL (2007) Classification and grading system for age-related macular degeneration. Int Ophthalmol Clin 47:51–63
doi: 10.1097/IIO.0b013e31802bd785
Ferris FL, Wilkinson CP, Bird A et al (2013) Clinical classification of age-related macular degeneration. Ophthalmology 120:844–851
doi: 10.1016/j.ophtha.2012.10.036
Neely DC, Bray KJ, Huisingh CE et al (2017) Prevalence of undiagnosed age-related macular degeneration in primary eye care. JAMA Ophthalmol 135:570. https://doi.org/10.1001/jamaophthalmol.2017.0830
doi: 10.1001/jamaophthalmol.2017.0830
pubmed: 28448669
pmcid: 5847085
Burlina PM, Joshi N, Pekala M et al (2017) Automated grading of age-related macular degeneration from color fundus images using deep convolutional neural networks. JAMA Ophthalmol 135:1170. https://doi.org/10.1001/jamaophthalmol.2017.3782
doi: 10.1001/jamaophthalmol.2017.3782
pubmed: 28973096
pmcid: 28973096
Kawaguchi A, Sharafeldin N, Sundaram A et al (2018) Tele-ophthalmology for age-related macular degeneration and diabetic retinopathy screening: A systematic review and meta-analysis. Telemed e-Health 24:301–308. https://doi.org/10.1089/tmj.2017.0100
doi: 10.1089/tmj.2017.0100
Pauleikhoff D, Barondes MJ, Minassian D et al (1990) Drusen as risk factors in age-related macular disease. Am J Ophthalmol 109:38–43
doi: 10.1016/S0002-9394(14)75576-X
Klein R, Klein BEK, Knudtson MD et al (2007) Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 114:253–262. https://doi.org/10.1016/j.ophtha.2006.10.040
doi: 10.1016/j.ophtha.2006.10.040
pubmed: 17270675
Klein ML, Ferris FL, Armstrong J et al (2008) Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology 115:1026–1031. https://doi.org/10.1016/j.ophtha.2007.08.030
doi: 10.1016/j.ophtha.2007.08.030
pubmed: 17981333
de Sisternes L, Simon N, Tibshirani R et al (2014) Quantitative SD-OCT imaging biomarkers as indicators of age-related macular degeneration progression. Investig Opthalmology Vis Sci 55:7093. https://doi.org/10.1167/iovs.14-14918
doi: 10.1167/iovs.14-14918
Schmidt-Erfurth U, Waldstein SM (2016) A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res 50:1–24. https://doi.org/10.1016/j.preteyeres.2015.07.007
doi: 10.1016/j.preteyeres.2015.07.007
pubmed: 26307399
Leuschen JN, Schuman SG, Winter KP et al (2013) Spectral-domain optical coherence tomography characteristics of intermediate age-related macular degeneration. Ophthalmology 120:140–150. https://doi.org/10.1016/j.ophtha.2012.07.004
doi: 10.1016/j.ophtha.2012.07.004
pubmed: 22968145
Schmidt-Erfurth U, Klimscha S, Waldstein SM, Bogunović H (2017) A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration. Eye 31:26–44. https://doi.org/10.1038/eye.2016.227
doi: 10.1038/eye.2016.227
pubmed: 27886184
Zweifel SA, Spaide RF, Curcio CA et al (2010) Reticular pseudodrusen are subretinal drusenoid deposits. Ophthalmology 117:303–312.e1. https://doi.org/10.1016/j.ophtha.2009.07.014
doi: 10.1016/j.ophtha.2009.07.014
pubmed: 19815280
Spaide RF, Curcio CA (2011) Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model. Retina 31:1609–1619. https://doi.org/10.1097/IAE.0b013e3182247535
doi: 10.1097/IAE.0b013e3182247535
pubmed: 21844839
pmcid: 3619110
Marsiglia M, Boddu S, Bearelly S et al (2013) Association between geographic atrophy progression and reticular pseudodrusen in eyes with dry age-related macular degeneration. Investig Ophthalmol Vis Sci 54:7362–7369. https://doi.org/10.1167/iovs.12-11073
doi: 10.1167/iovs.12-11073
Sohrab MA, Smith RT, Salehi-Had H et al (2011) Image registration and multimodal imaging of reticular pseudodrusen. Invest Ophthalmol Vis Sci 52:5743–5748. https://doi.org/10.1167/iovs.10-6942
doi: 10.1167/iovs.10-6942
pubmed: 21693600
Smith RT, Sohrab MA, Busuioc M, Barile G (2009) Reticular macular disease. Am J Ophthalmol 148:733–743.e2. https://doi.org/10.1016/j.ajo.2009.06.028
doi: 10.1016/j.ajo.2009.06.028
pubmed: 19878758
pmcid: 2786242
Ueda-Arakawa N, Ooto S, Tsujikawa A et al (2013) Sensitivity and specificity of detecting reticular pseudodrusen in multimodal imaging in Japanese patients. Retina 33:490–497. https://doi.org/10.1097/IAE.0b013e318276e0ae
doi: 10.1097/IAE.0b013e318276e0ae
pubmed: 23403515
Dolz-Marco R, Litts KM, Tan ACS et al (2017) The evolution of outer retinal tubulation, a neurodegeneration and gliosis prominent in macular diseases. Ophthalmology 124:1353–1367. https://doi.org/10.1016/j.ophtha.2017.03.043
doi: 10.1016/j.ophtha.2017.03.043
pubmed: 28456420
Hariri A, Nittala MG, Sadda SR (2015) Outer retinal tubulation as a predictor of the enlargement amount of geographic atrophy in age-related macular degeneration. Ophthalmology 122:407–413. https://doi.org/10.1016/j.ophtha.2014.08.035
doi: 10.1016/j.ophtha.2014.08.035
pubmed: 25315664
Sleiman K, Veerappan M, Winter KP et al (2017) Optical coherence tomography predictors of risk for progression to non-neovascular atrophic age-related macular degeneration. Ophthalmology 124:1764–1777. https://doi.org/10.1016/j.ophtha.2017.06.032
doi: 10.1016/j.ophtha.2017.06.032
pubmed: 28847641
pmcid: 5768932
Ferrara D, Silver RE, Louzada RN et al (2017) Optical coherence tomography features preceding the onset of advanced age-related macular degeneration. Invest Ophthalmol Vis Sci 58:3519–3529. https://doi.org/10.1167/iovs.17-21696
doi: 10.1167/iovs.17-21696
pubmed: 28715590
pmcid: 5512971
Yu JJ, Agrón E, Clemons TE et al (2018) Natural history of drusenoid pigment epithelial detachment associated with age-related macular degeneration. Ophthalmology. https://doi.org/10.1016/j.ophtha.2018.08.017
Holz FG, Sadda SR, Staurenghi G et al (2017) Imaging protocols in clinical studies in advanced age-related macular degeneration. Ophthalmology 124:464–478. https://doi.org/10.1016/j.ophtha.2016.12.002
doi: 10.1016/j.ophtha.2016.12.002
pubmed: 28109563
Schmitz-Valckenberg S, Sadda S, Staurenghi G et al (2016) Geographic atrophy: semantic considerations and literature review. Retina 36:2250–2264. https://doi.org/10.1097/IAE.0000000000001258
doi: 10.1097/IAE.0000000000001258
pubmed: 27552292
pmcid: 5115977
Mantel I, Zola M, De Massougnes S et al (2018) Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2018-312430
Chakravarthy U, Bailey CC, Johnston RL et al (2018) Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology 125:842–849. https://doi.org/10.1016/j.ophtha.2017.11.036
doi: 10.1016/j.ophtha.2017.11.036
pubmed: 29366564
Macular photocoagulation Study Group (1991) Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Arch Ophthalmol (Chicago, IL 1960) 109:1242–1257
doi: 10.1001/archopht.1991.01080090066027
Slakter JS, Yannuzzi LA, Guyer DR et al (1995) Indocyanine-green angiography. Curr Opin Ophthalmol 6:25–32
doi: 10.1097/00055735-199506000-00005
Cheung CMG, Lai TYY, Ruamviboonsuk P et al (2018) Polypoidal choroidal vasculopathy. Ophthalmology 125:708–724. https://doi.org/10.1016/j.ophtha.2017.11.019
doi: 10.1016/j.ophtha.2017.11.019
pubmed: 29331556
Brown D, Heier JS, Boyer DS et al (2017) Current best clinical practices—management of neovascular AMD. J Vitreoretin Dis 1:294–297. https://doi.org/10.1177/2474126417725946
doi: 10.1177/2474126417725946
Lupidi M, Cerquaglia A, Chhablani J et al (2018) Optical coherence tomography angiography in age-related macular degeneration: the game changer. Eur J Ophthalmol 28:349–357. https://doi.org/10.1177/1120672118766807
doi: 10.1177/1120672118766807
pubmed: 29623720
Al-Sheikh M, Iafe NA, Phasukkijwatana N et al (2018) Biomarkers of neovascular activity in age-related macular degeneration using optical coherence tomography angiography. Retina 38:220–230. https://doi.org/10.1097/IAE.0000000000001628
doi: 10.1097/IAE.0000000000001628
pubmed: 28582276
Spaide RF, Fujimoto JG, Waheed NK et al (2018) Optical coherence tomography angiography. Prog Retin Eye Res 64:1–55. https://doi.org/10.1016/j.preteyeres.2017.11.003
doi: 10.1016/j.preteyeres.2017.11.003
pubmed: 29229445
de Oliveira Dias JR, Zhang Q, Garcia JMB et al (2018) Natural history of subclinical neovascularization in nonexudative age-related macular degeneration using swept-source OCT angiography. Ophthalmology 125:255–266. https://doi.org/10.1016/j.ophtha.2017.08.030
doi: 10.1016/j.ophtha.2017.08.030
pubmed: 28964581
Barbazetto IA, Saroj N, Shapiro H et al (2010) Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol 149:939–946.e1. https://doi.org/10.1016/j.ajo.2010.01.007
doi: 10.1016/j.ajo.2010.01.007
pubmed: 20378094
Maguire MG, Daniel E, Shah AR et al (2013) Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120:2035–2041. https://doi.org/10.1016/j.ophtha.2013.03.017
doi: 10.1016/j.ophtha.2013.03.017
pubmed: 23706946
pmcid: 3758381
Owsley C, Clark ME, Huisingh CE et al (2016) Visual function in older eyes in normal macular health: association with incident early age-related macular degeneration 3 years later. Investig Opthalmology Vis Sci 57:1782. https://doi.org/10.1167/iovs.15-18962
doi: 10.1167/iovs.15-18962
Owsley C, Huisingh C, Clark ME et al (2015) Comparison of visual function in older eyes in the earliest stages of age-related macular degeneration to those in normal macular health. Curr Eye Res 41:1–7
Cocce KJ, Stinnett SS, Luhmann UFO et al (2018) Visual function metrics in early and intermediate dry age-related macular degeneration for use as clinical trial endpoints. Am J Ophthalmol 189:127–138. https://doi.org/10.1016/j.ajo.2018.02.012
doi: 10.1016/j.ajo.2018.02.012
pubmed: 29477964
pmcid: 6043161
Haymes SA, Roberts KF, Cruess AF et al (2006) The letter contrast sensitivity test: clinical evaluation of a new design. Invest Ophthalmol Vis Sci 47:2739–2745. https://doi.org/10.1167/iovs.05-1419
doi: 10.1167/iovs.05-1419
pubmed: 16723494
Hogg RE, Chakravarthy U (2006) Visual function and dysfunction in early and late age-related maculopathy. Prog Retin Eye Res 25:249–276. https://doi.org/10.1016/j.preteyeres.2005.11.002
doi: 10.1016/j.preteyeres.2005.11.002
pubmed: 16580242
Vujosevic S, Smolek MK, Lebow KA et al (2011) Detection of macular function changes in early (AREDS 2) and intermediate (AREDS 3) age-related macular degeneration. Ophthalmol J Int d’ophtalmologie Int J Ophthalmol Zeitschrift für Augenheilkd 225:155–160. https://doi.org/10.1159/000320340
doi: 10.1159/000320340
Jackson GR, Scott IU, Kim IK et al (2014) Diagnostic sensitivity and specificity of dark adaptometry for detection of age-related macular degeneration. Invest Ophthalmol Vis Sci 55:1427–1431. https://doi.org/10.1167/iovs.13-13745
doi: 10.1167/iovs.13-13745
pubmed: 24550363
pmcid: 3954002
Owsley C, McGwin G, Jackson GR et al (2007) Cone- and rod-mediated dark adaptation impairment in age-related maculopathy. Ophthalmology 114:1728–1735
doi: 10.1016/j.ophtha.2006.12.023
Laíns I, Miller JB, Park DH et al (2016) Structural changes associated with delayed dark adaptation in age-related macular degeneration. Ophthalmology. https://doi.org/10.1016/j.ophtha.2017.03.061
Velilla S, García-Medina JJ, García-Layana A et al (2013) Smoking and age-related macular degeneration: review and update. J Ophthalmol 2013:1–11. https://doi.org/10.1155/2013/895147
doi: 10.1155/2013/895147
Garcia-Layana A, Cabrera-López F, García-Arumí J et al (2017) Early and intermediate age-related macular degeneration: update and clinical review. Clin Interv Aging 12:1579–1587. https://doi.org/10.2147/CIA.S142685
doi: 10.2147/CIA.S142685
pubmed: 29042759
pmcid: 5633280
Cong R, Zhou B, Sun Q et al (2008) Smoking and the risk of age-related macular degeneration: a meta-analysis. Ann Epidemiol 18:647–656. https://doi.org/10.1016/j.annepidem.2008.04.002
doi: 10.1016/j.annepidem.2008.04.002
pubmed: 18652983
Khan JC, Thurlby DA, Shahid H et al (2006) Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 90:75–80. https://doi.org/10.1136/bjo.2005.073643
doi: 10.1136/bjo.2005.073643
pubmed: 16361672
pmcid: 1856879
Pennington KL, DeAngelis MM (2016) Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis 3:34. https://doi.org/10.1186/s40662-016-0063-5
doi: 10.1186/s40662-016-0063-5
Chapman NA, Jacobs RJ, Braakhuis AJ (2018) Role of diet and food intake in age-related macular degeneration: a systematic review. Clin Exp Ophthalmol. https://doi.org/10.1111/ceo.13343
Clemons TE, Milton RC, Klein R et al (2005) Risk factors for the incidence of advanced age-related macular degeneration in the age-related eye disease study (AREDS) AREDS report no. 19. Ophthalmology 112:533–539.e1. https://doi.org/10.1016/j.ophtha.2004.10.047
doi: 10.1016/j.ophtha.2004.10.047
pubmed: 15808240
Age-Related Eye Disease Study 2 Research Group (2013) Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 309:2005–2015
doi: 10.1001/jama.2013.4997
Vavvas DG, Small KW, Awh CC et al (2018) CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation. Proc Natl Acad Sci U S A 115:E696–E704. https://doi.org/10.1073/pnas.1718059115
doi: 10.1073/pnas.1718059115
pubmed: 29311295
pmcid: 5789949
Assel MJ, Li F, Wang Y et al (2018) Genetic polymorphisms of CFH and ARMS2 do not predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology 125:391–397. https://doi.org/10.1016/j.ophtha.2017.09.008
doi: 10.1016/j.ophtha.2017.09.008
pubmed: 29032853
Chew EY, Klein ML, Clemons TE et al (2015) Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test? Ophthalmology 122:212–215. https://doi.org/10.1016/j.ophtha.2014.10.012
doi: 10.1016/j.ophtha.2014.10.012
pubmed: 25456150
Pearlman J (2015) Re: Chew et al.: Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test? (Ophthalmology 2015;122:212-5). Ophthalmology 122:e60–e61. https://doi.org/10.1016/j.ophtha.2015.01.031
doi: 10.1016/j.ophtha.2015.01.031
pubmed: 26398058
Awh CC, Zanke B (2015) Re: Chew et al.: Genetic testing in persons with age-related macular degeneration and the use of AREDS supplements: to test or not to test? (Ophthalmology 2015;122:212-5). Ophthalmology 122:e62–e63. https://doi.org/10.1016/j.ophtha.2015.03.028
doi: 10.1016/j.ophtha.2015.03.028
pubmed: 26398061
Chew EY, Klein ML, Clemons TE et al (2014) No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology 121:2173–2180. https://doi.org/10.1016/j.ophtha.2014.05.008
doi: 10.1016/j.ophtha.2014.05.008
pubmed: 24974817
pmcid: 4253656
Klein ML, Francis PJ, Rosner B et al (2008) CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 115:1019–1025. https://doi.org/10.1016/j.ophtha.2008.01.036
doi: 10.1016/j.ophtha.2008.01.036
pubmed: 18423869
Awh CC, Lane A-M, Hawken S et al (2013) CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology 120:2317–2323. https://doi.org/10.1016/j.ophtha.2013.07.039
doi: 10.1016/j.ophtha.2013.07.039
pubmed: 23972322
Assel MJ, Li F, Wang Y et al (2018) Genetic polymorphisms of CFH and ARMS2 do not predict response to antioxidants and zinc in patients with age-related macular degeneration: independent statistical evaluations of data from the Age-Related Eye Disease Study. Ophthalmology 125:391–397. https://doi.org/10.1016/j.ophtha.2017.09.008
doi: 10.1016/j.ophtha.2017.09.008
pubmed: 29032853
Faes L, Bodmer NS, Bachmann LM et al (2014) Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis. Eye (Lond) 28:788–796. https://doi.org/10.1038/eye.2014.104
doi: 10.1038/eye.2014.104
Rauch R, Weingessel B, Maca SM, Vecsei-Marlovits PV (2012) Time to first treatment: the significance of early treatment of exudative age-related macular degeneration. Retina 32:1260–1264. https://doi.org/10.1097/IAE.0b013e3182018df6
doi: 10.1097/IAE.0b013e3182018df6
pubmed: 22186738
AREDS2-HOME Study Research Group, Chew EY, Clemons TE et al (2014) Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology 121:535–544. https://doi.org/10.1016/j.ophtha.2013.10.027
doi: 10.1016/j.ophtha.2013.10.027
Fritsche LG, Fariss RN, Stambolian D et al (2014) Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet 15:151–171
doi: 10.1146/annurev-genom-090413-025610
Fritsche LG, Igl W, Bailey JNC et al (2016) A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet 48:134–143. https://doi.org/10.1038/ng.3448
doi: 10.1038/ng.3448
pubmed: 26691988
Holz FG, Sadda SR, Busbee B et al (2018) Efficacy and safety of Lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol 136:666–677. https://doi.org/10.1001/jamaophthalmol.2018.1544
doi: 10.1001/jamaophthalmol.2018.1544
pubmed: 29801123
pmcid: 6145777
Yehoshua Z, Alexandre de Amorim Garcia Filho C, Nunes RP et al (2014) Systemic complement inhibition with Eculizumab for geographic atrophy in age-related macular degeneration. Ophthalmology 121:693–701. https://doi.org/10.1016/j.ophtha.2013.09.044
doi: 10.1016/j.ophtha.2013.09.044
pubmed: 24289920
Moore NA, Bracha P, Hussain RM et al (2017) Gene therapy for age-related macular degeneration. Expert Opin Biol Ther 17:1235–1244. https://doi.org/10.1080/14712598.2017.1356817
doi: 10.1080/14712598.2017.1356817
pubmed: 28726562
Singh MS, MacLaren RE (2018) Stem cell treatment for age-related macular degeneration: the challenges. Investig Opthalmology Vis Sci 59:AMD78. https://doi.org/10.1167/iovs.18-24426
doi: 10.1167/iovs.18-24426
Manyak MJ, Russo A, Smith PD, Glatstein E (1988) Photodynamic therapy. J Clin Oncol 6:380–391. https://doi.org/10.1200/JCO.1988.6.2.380
doi: 10.1200/JCO.1988.6.2.380
pubmed: 2963095
Zhou CN (1989) Mechanisms of tumor necrosis induced by photodynamic therapy. J Photochem Photobiol B 3:299–318
doi: 10.1016/1011-1344(89)80035-1
Miller JW, Walsh AW, Kramer M et al (1995) Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol (Chicago Ill 1960) 113:810–818
doi: 10.1001/archopht.1995.01100060136048
Schmidt-Erfurth U, Hasan T, Gragoudas E et al (1994) Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 101:1953–1961
doi: 10.1016/S0161-6420(13)31079-3
Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol (Chicago Ill 1960) 119:198–207
Verteporfin In Photodynamic Therapy Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541–560
doi: 10.1016/S0002-9394(01)00967-9
Koh A, Lai TYY, Takahashi K et al (2017) Efficacy and safety of Ranibizumab with or without Verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. JAMA Ophthalmol 135:1206. https://doi.org/10.1001/jamaophthalmol.2017.4030
doi: 10.1001/jamaophthalmol.2017.4030
pubmed: 28983556
pmcid: 5710379
Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29:10–14. https://doi.org/10.1053/sonc.2002.37264
doi: 10.1053/sonc.2002.37264
pubmed: 12516033
Takahashi H, Shibuya M (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109:227–241. https://doi.org/10.1042/CS20040370
doi: 10.1042/CS20040370
Keyt BA, Berleau LT, Nguyen HV et al (1996) The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271:7788–7795
doi: 10.1074/jbc.271.13.7788
Houck KA, Ferrara N, Winer J et al (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806–1814. https://doi.org/10.1210/mend-5-12-1806
doi: 10.1210/mend-5-12-1806
pubmed: 1791831
Ng EWM, Shima DT, Calias P et al (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123–132. https://doi.org/10.1038/nrd1955
doi: 10.1038/nrd1955
pubmed: 16518379
Gragoudas ES, Adamis AP, Cunningham ET et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805–2816. https://doi.org/10.1056/NEJMoa042760
doi: 10.1056/NEJMoa042760
pubmed: 15625332
VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP et al (2006) Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113:1508.e1–1508.25. https://doi.org/10.1016/j.ophtha.2006.02.064
doi: 10.1016/j.ophtha.2006.02.064
Lowe J, Araujo J, Yang J et al (2007) Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 85:425–430. https://doi.org/10.1016/j.exer.2007.05.008
doi: 10.1016/j.exer.2007.05.008
pubmed: 17714704
Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431. https://doi.org/10.1056/NEJMoa054481
doi: 10.1056/NEJMoa054481
pubmed: 17021318
Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444. https://doi.org/10.1056/NEJMoa062655
doi: 10.1056/NEJMoa062655
pubmed: 17021319
Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57–65.e5. https://doi.org/10.1016/j.ophtha.2008.10.018
doi: 10.1016/j.ophtha.2008.10.018
pubmed: 19118696
Ferrara N, Hillan KJ, Gerber H-P, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391–400. https://doi.org/10.1038/nrd1381
doi: 10.1038/nrd1381
pubmed: 15136787
Michels S, Rosenfeld PJ, Puliafito CA et al (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035–1047. https://doi.org/10.1016/j.ophtha.2005.02.007
doi: 10.1016/j.ophtha.2005.02.007
pubmed: 15936441
Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331–335
doi: 10.3928/1542-8877-20050701-14
Holz FG, Amoaku W, Donate J et al (2011) Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 118:663–671. https://doi.org/10.1016/j.ophtha.2010.12.019
doi: 10.1016/j.ophtha.2010.12.019
pubmed: 21459217
(2008) Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF trap - Regeneron, VEGF trap (R1R2), VEGF trap-eye. Drugs R D 9:261–269
Stewart MW, Rosenfeld PJ (2008) Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol 92:667–668. https://doi.org/10.1136/bjo.2007.134874
doi: 10.1136/bjo.2007.134874
pubmed: 18356264
Heier JS, Brown DM, Chong V et al (2012) Intravitreal Aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548. https://doi.org/10.1016/j.ophtha.2012.09.006
doi: 10.1016/j.ophtha.2012.09.006
pubmed: 23084240
Dugel PU, Jaffe GJ, Sallstig P et al (2017) Brolucizumab versus Aflibercept in participants with neovascular age-related macular degeneration: A randomized trial. Ophthalmology 124:1296–1304. https://doi.org/10.1016/j.ophtha.2017.03.057
doi: 10.1016/j.ophtha.2017.03.057
pubmed: 28551167
Dugel PU, Koh A, Ogura Y et al (2020) HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of Brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127. https://doi.org/10.1016/J.OPHTHA.2019.04.017
Lalwani GA, Rosenfeld PJ, Fung AE et al (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 148:43–58.e1. https://doi.org/10.1016/j.ajo.2009.01.024
doi: 10.1016/j.ajo.2009.01.024
pubmed: 19376495
Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and Bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 119:1388–1398. https://doi.org/10.1016/j.ophtha.2012.03.053
doi: 10.1016/j.ophtha.2012.03.053
pubmed: 22555112
pmcid: 3389193
Chakravarthy U, Harding SP, Rogers CA et al (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet (London, England) 382:1258–1267. https://doi.org/10.1016/S0140-6736(13)61501-9
doi: 10.1016/S0140-6736(13)61501-9
Berg K, Hadzalic E, Gjertsen I et al (2016) Ranibizumab or Bevacizumab for Neovascular age-related macular degeneration according to the Lucentis compared to Avastin study treat-and-extend protocol. Ophthalmology 123:51–59. https://doi.org/10.1016/j.ophtha.2015.09.018
doi: 10.1016/j.ophtha.2015.09.018
pubmed: 26477842
Berg K, Pedersen TR, Sandvik L, Bragadóttir R (2015) Comparison of Ranibizumab and Bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146–152. https://doi.org/10.1016/j.ophtha.2014.07.041
doi: 10.1016/j.ophtha.2014.07.041
pubmed: 25227499
Silva R, Berta A, Larsen M et al (2018) Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with Ranibizumab from the TREND study. Ophthalmology 125:57–65. https://doi.org/10.1016/j.ophtha.2017.07.014
doi: 10.1016/j.ophtha.2017.07.014
pubmed: 28893454
Gregori NZ, Flynn HW, Schwartz SG et al (2015) Current infectious endophthalmitis rates after Intravitreal injections of anti-vascular endothelial growth factor agents and outcomes of treatment. Ophthalmic Surg Lasers Imaging Retina 46:643–648. https://doi.org/10.3928/23258160-20150610-08
doi: 10.3928/23258160-20150610-08
pubmed: 26114845
McCannel CA (2011) Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 31:654–661. https://doi.org/10.1097/IAE.0b013e31820a67e4
doi: 10.1097/IAE.0b013e31820a67e4
Rayess N, Rahimy E, Storey P et al (2016) Postinjection endophthalmitis rates and characteristics following intravitreal Bevacizumab, Ranibizumab, and Aflibercept. Am J Ophthalmol 165:88–93. https://doi.org/10.1016/j.ajo.2016.02.028
doi: 10.1016/j.ajo.2016.02.028
pubmed: 26944277
Thavikulwat AT, Jacobs-El N, Kim JS et al (2017) Evolution of geographic atrophy in participants treated with Ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retin 1:34–41. https://doi.org/10.1016/j.oret.2016.09.005
doi: 10.1016/j.oret.2016.09.005
Good TJ, Kimura AE, Mandava N, Kahook MY (2011) Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 95:1111–1114. https://doi.org/10.1136/bjo.2010.180729
doi: 10.1136/bjo.2010.180729
pubmed: 20702430
Hoang QV, Tsuang AJ, Gelman R et al (2013) Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina 33:179–187. https://doi.org/10.1097/IAE.0b013e318261a6f7
doi: 10.1097/IAE.0b013e318261a6f7
pubmed: 22990314
Rofagha S, Bhisitkul RB, Boyer DS et al (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120:2292–2299. https://doi.org/10.1016/j.ophtha.2013.03.046
doi: 10.1016/j.ophtha.2013.03.046
pubmed: 23642856
Forooghian F, Cukras C, Meyerle CB et al (2009) Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 29:723–731. https://doi.org/10.1097/IAE.0b013e3181a2c1c3
doi: 10.1097/IAE.0b013e3181a2c1c3
pubmed: 19516114
pmcid: 2770842
Gasperini JL, Fawzi AA, Khondkaryan A et al (2012) Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 96:14–20. https://doi.org/10.1136/bjo.2011.204685
doi: 10.1136/bjo.2011.204685
pubmed: 21791509
Messenger WB, Campbell JP, Faridi A et al (2014) Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration. Br J Ophthalmol 98:1205–1207. https://doi.org/10.1136/bjophthalmol-2013-304829
doi: 10.1136/bjophthalmol-2013-304829
pubmed: 24795334
Ferrone PJ, Anwar F, Naysan J et al (2014) Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration. Br J Ophthalmol 98(Suppl 1):i17–i21. https://doi.org/10.1136/bjophthalmol-2013-304474
doi: 10.1136/bjophthalmol-2013-304474
pubmed: 24795335
pmcid: 4033176
Aslankurt M, Aslan L, Aksoy A et al (2013) The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration. Eur J Ophthalmol 23:553–557. https://doi.org/10.5301/ejo.5000268
doi: 10.5301/ejo.5000268
pubmed: 23516253
Schachat AP (2013) Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Am J Ophthalmol 156 e1:1–2. https://doi.org/10.1016/j.ajo.2013.04.009
doi: 10.1016/j.ajo.2013.04.009
Ehlken C, Jungmann S, Böhringer D et al (2014) Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye (Lond) 28:538–545. https://doi.org/10.1038/eye.2014.64
doi: 10.1038/eye.2014.64
Wykoff CC, Hariprasad SM, Zhou B (2018) Innovation in Neovascular age-related macular degeneration: consideration of Brolucizumab, Abicipar, and the port delivery system. Ophthalmic Surgery, Lasers Imaging Retina 49:913–917. https://doi.org/10.3928/23258160-20181203-01
doi: 10.3928/23258160-20181203-01
pubmed: 30566697
Campochiaro PA, Marcus DM, Awh CC et al (2019) The port delivery system with Ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial. Ophthalmology 126. https://doi.org/10.1016/J.OPHTHA.2019.03.036
Siddiqui F, Aziz A, Khanani A (2020) retinal physician - gene therapy for neovascular AMD. https://www.retinalphysician.com/issues/2020/special-edition-2020/gene-therapy-for-neovascular-amd . Accessed 17 Mar 2020
Yonekawa Y, Miller JW, Kim IK (2015) Age-related macular degeneration: advances in management and diagnosis. J Clin Med 4:343–359
doi: 10.3390/jcm4020343